Reports full year 2023 revenue of $50.6 million and non-GAAP adjusted EBITDA loss of $11.6 millionReaffirms expected release of topline pivotal clinical data for Anaphylm™ (epinephrine) Sublingual Film in March 2024Reaffirms anticipated FDA decision on Libervant™ (diazepam) Buccal Film application in April 2024Provides full year 2024 financial guidanceHosts investment community conference call on March 6, 2024 WARREN, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pha ...

公司业务 - Aquestive Therapeutics, Inc.是一家制药公司，通过创新科学和传递技术推进药物，目前有五种已授权的商业化产品[207] - 我们的收入主要来自为许可方定制生产产品，自主开发的Sympazan产品的收入，以及与客户签订的产品开发服务合同[208] - 未来的制造和供应收入将取决于现有授权产品的需求量，以及成功产品开发合作的许可和供应协议[209] 收入来源 - 我们通过许可知识产权获得许可和版税收入，根据协议条款，这些收入可能会在许可协议的期限内记录[212] - 我们的首个专有CNS产品Sympazan于2018年12月上市，销售收入净额包括折扣、批发商服务费、退货津贴、回扣和共付支持赎回等[213] 成本和费用 - 我们的成本和费用主要来自制造和供应收入、自主产品候选品管道的开发、销售、一般和行政费用等方面[214] - 我们的研发费用主要包括员工相关费用、外部研发费用、临床研究材料的获取成本等[217] - 销售、一般和行政费用主要包括薪资、福利、股权补偿等成本，以及专利相关和其他法律费用、咨询费用等[220] 财务状况 - 2023年，A公司的总收入为50,583千美元，较2022年增长6%或2,903千美元[228] - A公司截至2023年12月31日拥有23,872千美元的现金及现金等价物，通过ATM设施和股权资本市场提供资金支持[231] 筹资活动 - 公司需要筹集额外资金以继续推进其临床项目，通过ATM设施和林肯公园购买协议等资本市场获得资金[237] - 公司计划继续投资于Anaphylm和AQST-108等产品开发活动，直至实现盈利，需要额外资金或融资[240]

经纪推荐 - 投资者在做出股票买入、卖出或持有决策之前通常会参考华尔街分析师的推荐[1] - Aquestive Therapeutics目前的平均经纪推荐（ABR）为1.00，表示强烈买入[2] - 所有推荐中有四个是强烈买入，占比100%[3] - 经纪推荐虽然建议购买Aquestive Therapeutics，但不应仅凭此信息做出投资决定[4]

In the latest market close, Aquestive Therapeutics (AQST) reached $3.67, with a +0.55% movement compared to the previous day. The stock exceeded the S&P 500, which registered a gain of 0.52% for the day. Meanwhile, the Dow experienced a rise of 0.12%, and the technology-dominated Nasdaq saw an increase of 0.9%.The specialty pharmaceutical company's stock has climbed by 52.72% in the past month, exceeding the Medical sector's gain of 5.15% and the S&P 500's gain of 3.85%.The investment community will be clos ...

Aquestive Therapeutics (AQST) is expected to report fourth-quarter and full-year 2023 results later this month or early next month. In the last reported quarter, the company beat earnings expectations by 72.73%.Factors to ConsiderAquestive earns royalty revenues from its five out-licensed marketed products that it supplies under license deals with partners. Aquestive is the exclusive manufacturer of these licensed products. Its revenues from these products are expected to have increased in the fourth quarte ...

股价表现 - Aquestive Therapeutics (AQST) 最新收盘价为$2.65，较前一天下跌了1.67%[1] - 过去一个月，这家专业制药公司的股价上涨了7.37%，表现优于医疗行业的4.52%和标普500指数的3.56%[2] 财务预测 - 分析师预计Aquestive Therapeutics的下一个财报将每股亏损$0.08，同比增长65.22%；预计营收为$11.79百万美元，同比增长10.36%[3] 业务趋势 - 近期分析师对Aquestive Therapeutics的估值变动可能反映了最新的短期业务趋势[4]

The clinical trial data show that epinephrine delivered via orally administered Anaphylm™ (epinephrine) Sublingual Film is comparable to epinephrine delivered via autoinjector or manual intramuscular (IM) injection.Anaphylm candidate, with the potential to be the first and only non-invasive, orally delivered epinephrine product, demonstrates clinical results comparable to autoinjectors (such as EpiPen® and Auvi-Q®) for the emergency treatment of severe allergic reactions, including anaphylaxis. A Phase 3 pi ...

Aquestive Therapeutics (AQST) closed at $2.68 in the latest trading session, marking a +1.13% move from the prior day. The stock's change was more than the S&P 500's daily gain of 0.96%. Elsewhere, the Dow saw an upswing of 0.4%, while the tech-heavy Nasdaq appreciated by 1.3%.Heading into today, shares of the specialty pharmaceutical company had lost 0.19% over the past month, lagging the Medical sector's gain of 1.18% and the S&P 500's gain of 3.69% in that time.The upcoming earnings release of Aquestive ...

Aquestive Therapeutics (AQST) ended the recent trading session at $2.68, demonstrating a +1.52% swing from the preceding day's closing price. The stock's change was more than the S&P 500's daily gain of 0.06%. Meanwhile, the Dow gained 0.13%, and the Nasdaq, a tech-heavy index, added 0.24%.Shares of the specialty pharmaceutical company have appreciated by 3.13% over the course of the past month, underperforming the Medical sector's gain of 3.52% and the S&P 500's gain of 6.45%.Market participants will be cl ...

The latest trading session saw Aquestive Therapeutics (AQST) ending at $2.63, denoting a -1.5% adjustment from its last day's close. This change lagged the S&P 500's daily gain of 1.07%. Elsewhere, the Dow gained 0.35%, while the tech-heavy Nasdaq added 1.74%.Heading into today, shares of the specialty pharmaceutical company had gained 18.14% over the past month, outpacing the Medical sector's gain of 4.02% and the S&P 500's gain of 2.93% in that time.The investment community will be paying close attention ...